Viridian Therapeutics, Inc.\DE (VRDN) Interest Expenses (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Interest Expenses history runs 14 years deep, the most recent figure standing at $3.5 million for Q1 2026.

• In Q1 2026, Interest Expenses rose 529.45% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $8.2 million (up 383.58% YoY), while the FY2025 annual figure was $316.8 million, up 51.95% from the prior year.
• Interest Expenses for Q1 2026 stood at $3.5 million, down from $3.6 million in the prior quarter.
• The five-year high for Interest Expenses was $15.5 million in Q3 2024, with the low at -$7000.0 in Q4 2022.
• The 5-year median for Interest Expenses is $555000.0 (2025), against an average of $2.0 million.
• The sharpest annual moves came in 2022 and 2023: Interest Expenses slumped 103.5% in 2022, then jumped 5814.29% in 2023.
• Viridian Therapeutics, Inc.\DE's Interest Expenses stood at -$7000.0 in 2022, then surged by 5814.29% to $400000.0 in 2023, then tumbled by 65.0% to $140000.0 in 2024, then surged by 2461.43% to $3.6 million in 2025, then slipped by 3.46% to $3.5 million in 2026.
• Business Quant data shows VRDN's Interest Expenses at $3.5 million in Q1 2026, $3.6 million in Q4 2025, and $560000.0 in Q3 2025.